FindTrial
Sign In

Effect of Apple Cider Vinegar on Blood Sugar in People with Type 2 Diabetes

Assessing the Impact of Apple Cider Vinegar in Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/100976
Enrollment
140
Registered
2026-01-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Apple cider vinegar powder: Investigational product: Apple cider vinegar (ACV) Formulation: Capsule containing 1500 mg lyophilized apple cider vinegar powder Dose: 1500 mg Frequency: On

Sponsors

AIIMS-Deoghar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Adult patients of either gender, aged 18 60 years. -Diagnosed cases of Type 2 Diabetes Mellitus as per standard diagnostic criteria. -HbA1c > 7.0% at the time of screening. -Patients on stable antidiabetic therapy (oral hypoglycemic agents with or without insulin) for at least 3 months prior to enrollment. -Willingness to maintain current diet and lifestyle practices during the study period. -Ability to understand the study procedures and provide written informed consent

Exclusion criteria

Exclusion criteria: -Patients with known chronic kidney disease (eGFR -History of cardiovascular diseases, including ischemic heart disease, stroke, or heart failure. -Known allergy or intolerance to vinegar or apple-derived products, as reported by the patient or relatives.

Design outcomes

Primary

MeasureTime frame
To determine the effect of ACV on HbA1c in T2DMTimepoint: Outcome measures will be evaluated at baseline (0 month), at 3 months, and at 6 months of intervention.—

Secondary

MeasureTime frame
Blood sugar fasting (BSF): Before the start of intervention and after intervention 5 ml venous blood sample will be taken with 12 hours fasting for biochemical analysis of blood sugar fasting Fasting lipid profile: Before the start of intervention and after intervention 5 ml venous blood sample was taken with 12 hours fasting for biochemical analysis of fasting lipid profile Anthropometric measurements: Height, weight, Hip/waist ratio and mid upper Timepoint: 0,3 and 6 months—

Countries

India

Contacts

Public ContactSubodh Kumar

AIIMS, Deoghar

drsubodh27@gmail.com9560137157

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026